f16il2
mAbexperimentalADC
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT01134250)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109583 ↗
Also known as
- f16il2
- f16il2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05468294 | Phase 1/Phase 2 (Phase 2) | Mar 9, 2017 | Philogen S.p.A. |
| NCT03207191 | Phase 1 | Nov 30, 2016 | Boehringer Ingelheim, Philogen S.p.A. |
| NCT02957032 | Phase 1 | Jan 1, 2016 | Philogen S.p.A. |
| NCT02054884 | Phase 2 | Oct 1, 2013 | immatics Biotechnologies GmbH, Medical University of Graz, Philogen S.p.A. |
| NCT01131364 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2008 | Philogen S.p.A., University of Milan |
| NCT01134250 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2008 | Philogen S.p.A., University of Milan |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Philogen S.p.A. | For profit | 6 | 6 | 2 | 2008 |
| University of Milan | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2016 |
| immatics Biotechnologies GmbH | For profit | 1 | 0 | 1 | 2013 |
| Medical University of Graz | Academic/Hospital | 1 | 0 | 1 | 2013 |
5 organizations
Page 1 / 1